Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Anokion allies with Astellas and forms Kanyos to develop compounds

Executive Summary

Astellas Pharma Inc. and Anokion SA are teaming up to develop compounds for Type I diabetes and celiac disease. Anokion created Kanyos Bio Inc. to develop the candidates and the spin-off concurrently raised $16mm from Astellas, individual investors, and Anokion's Series A backers Versant Ventures, Novo Ventures, and Novartis Venture Fund.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes M&A Option
    • R&D and Marketing (Licensing)

Related Companies